Resemblances and differences between osteoradionecrosis of the jaw and medication-related osteonecrosis of the jaw.

medication-related osteonecrosis of the jaw osteonecrosis of the jaw osteoradionecrosis of the jaw treatment strategies

Journal

Medicine and pharmacy reports
ISSN: 2668-0572
Titre abrégé: Med Pharm Rep
Pays: Romania
ID NLM: 101742144

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 25 01 2023
revised: 26 02 2023
accepted: 13 03 2023
medline: 12 2 2024
pubmed: 12 2 2024
entrez: 12 2 2024
Statut: ppublish

Résumé

The aim of this retrospective study was to identify the clinical, radiological, and histological characteristics of patients diagnosed with osteonecrosis of the jaw (ONJ) and treated at the Oral and Maxillo-Facial Surgery Clinic of the Emergency Clinical County Hospital of Targu Mures between 2017 and 2022. The study aimed to analyze correlations between patient characteristics, particularly their history of bone modifying agent use or local radiotherapy during cancer treatment, in order to identify specific patient profiles that could aid in evaluating treatment response and guide individualized treatment strategies. Fifty-two patients diagnosed with ONJ were included in the study. The patients were divided into two groups based on their medical history: the bone modifying agent use group and the radiotherapy group. Clinical, radiological, and histological data were collected and analyzed. Statistical analysis, including p-values, was performed to compare patient characteristics between the two groups. Patients in the radiotherapy group were significantly older than those in the bone modifying agent use group (66 years vs. 56.9 years, p=0.001). There was a higher proportion of males in the radiotherapy group compared to the bone modifying agent use group (90% vs. 22%, p<0.001). Jaw involvement was more prevalent in the radiotherapy group compared to the bone modifying agent use group (95% vs. 66%, p=0.018). Histological analysis showed a similar frequency of Actinomyces species in both groups (50% vs. 34%, p=0.264). The findings of this study suggest the existence of two distinct patient profiles based on their treatment history (bone modifying agent use vs. radiotherapy) in ONJ. Patients in the radiotherapy group were older, predominantly male, and exhibited a higher prevalence of jaw involvement. Histological analysis revealed no significant differences in Actinomyces species frequency between the two groups. These distinct patient profiles may indicate different responses to treatment, emphasizing the need for individualized treatment strategies tailored to specific patient characteristics. Further research is warranted to validate these findings and develop personalized approaches for managing ONJ.

Identifiants

pubmed: 38344330
doi: 10.15386/mpr-2610
pii: cm-97-76
pmc: PMC10852124
doi:

Types de publication

Journal Article

Langues

eng

Pagination

76-83

Références

Head Neck. 2003 Mar;25(3):181-6
pubmed: 12599284
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22(1):e43-e57
pubmed: 27918742
Oral Maxillofac Surg. 2018 Mar;22(1):59-63
pubmed: 29224060
Int Dent J. 2018 Feb;68(1):22-30
pubmed: 28649774
Br J Oral Maxillofac Surg. 2014 May;52(5):392-5
pubmed: 24725905
Antibiotics (Basel). 2022 Apr 24;11(5):
pubmed: 35625212
Med Pharm Rep. 2023 Jul;96(3):323-327
pubmed: 37577019
J Craniomaxillofac Surg. 2016 Mar;44(3):265-70
pubmed: 26782845
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12
pubmed: 19371809
J Stomatol Oral Maxillofac Surg. 2021 Nov;122(5):499-504
pubmed: 32827811
Br J Oral Maxillofac Surg. 2008 Dec;46(8):653-60
pubmed: 18562055
J Transl Med. 2017 Jun 6;15(1):128
pubmed: 28587628
J Dent Sci. 2021 Jul;16(3):885-890
pubmed: 34141102
J Maxillofac Oral Surg. 2015 Dec;14(4):891-901
pubmed: 26604460
J Oral Maxillofac Surg. 2022 May;80(5):920-943
pubmed: 35300956
Morphologie. 2021 Jun;105(349):170-187
pubmed: 33281055
Med Oral Patol Oral Cir Bucal. 2019 May 1;24(3):e326-e338
pubmed: 31011143
Am J Clin Oncol. 2002 Apr;25(2):168-71
pubmed: 11943896
Oncol Lett. 2017 Jul;14(1):127-136
pubmed: 28693144
J Int Med Res. 2022 Jun;50(6):3000605221104186
pubmed: 35698727

Auteurs

Mihai Vlad Golu (MV)

Department of Oral and Maxillofacial Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania.
IOSUD Doctoral School, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania.

Ionela Paşcanu (I)

Department of Endocrinology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania.

Cecilia Petrovan (C)

Department of Oral and Maxillofacial Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania.

Simona Mocan (S)

Department of Pathology, Emergency County Hospital, Targu Mures, Romania.

Adina Cosarcă (A)

Department of Oral and Maxillofacial Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania.

Despina Bereczki Temistocle (DB)

Department of Oral and Maxillofacial Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania.
IOSUD Doctoral School, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania.

Alina Ormenişan (A)

Department of Oral and Maxillofacial Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania.

Classifications MeSH